ClinicalTrials.gg
CompletedNCT00549718Updated Jun 11, 2014Results posted

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

A Phase 3 interventional study of Lurasidone HCl in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 48 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-06-11.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
489
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
4th of 39
489 · median 149
Started
2007
the only one that year
Phase 3
18 of 39
none open now
Registered
5th of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 4th largest by enrollment, is the only one that started in 2007, is one of 18 in phase 3, and was the 5th registered.

Schizophrenia

3,567 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • SM-13496
  • Latuda
  • Lurasidone
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to enter the study, each patient must comply with the following inclusion criteria:

  • Provide written and aged between 18 and 75 years of age.
  • Meets ™ criteria for a primary diagnosis of schizophrenia.
  • Not pregnant, if of agrees to remain abstinent or use adequate and reliable for duration of study.
  • Able and agrees to remain off prior antipsychotic medication for the duration of study.
  • Good physical health on the basis of medical history, physical examination, and laboratory screening.
  • Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.

Exclusion criteria

Exclusion Criteria:

  • Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
  • Any chronic organic disease of the CNS (other than schizophrenia)
  • Used compound within 30 days.
  • or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
489 participants (actual)

Study arms

  • Experimental
    Lurasidone 40mg

    Drug: Lurasidone HCl

  • Experimental
    Lurasidone 80mg

    Drug: Lurasidone HCl

  • Experimental
    Lurasidone 120mg

    Drug: Lurasidone HCl

  • Placebo comparator
    Sugar Pill

    Drug: Lurasidone HCl

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Total PANSS Score From Baseline to the End of the Double Blind Phase

    The PANSS is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.

    Time frame: 6 weeks

Secondary outcomes

  1. CGI-S From Baseline to the End of the Double-blind Treatment

    Clinical Global Impression of Severity is a clinician-rated assessment of the subject's current illness state on a 7 point scale, where a higher score is associated with greater illness severity. The scale has a single item measured on a 7 point scale from 1 ('normal', not ill) to 7 (extremely ill).

    Time frame: 6 weeks

07

Results

Posted Dec 14, 2010

Participant flow

Participant flow — Overall Study
MilestoneLurasidone 40mgLurasidone 80mgLurasidone 120mgPlacebo
Started125123124128
Completed84868573
Not completed41373955
Withdrew: Insufficient clinical response2071832
Withdrew: Adverse event6873
Withdrew: Lost to follow-up4206
Withdrew: Withdrawal by subject9181213
Withdrew: Administrative2221

Outcome measures

SecondaryCGI-S From Baseline to the End of the Double-blind Treatment

Clinical Global Impression of Severity is a clinician-rated assessment of the subject's current illness state on a 7 point scale, where a higher score is associated with greater illness severity. The scale has a single item measured on a 7 point scale from 1 ('normal', not ill) to 7 (extremely ill).

Time frame:
6 weeks
Reported as:
Least squares mean · scores on a scale
CGI-S From Baseline to the End of the Double-blind Treatment
scores on a scaleLurasidone 40mgLurasidone 80mgLurasidone 120mgPlacebo
CGI-S From Baseline to the End of the Double-blind Treatment-1.1 (-1.3 to -0.9)-1.4 (-1.6 to -1.2)-1.2 (-1.4 to -1.0)-1.0 (-1.2 to -0.8)
Statistical analysis
  • Lurasidone 40mg vs Lurasidone 80mg vs Lurasidone 120mg vs Placebo · Mixed Models Analysis · p = <0.05
PrimaryChange in Total PANSS Score From Baseline to the End of the Double Blind Phase

The PANSS is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.

Time frame:
6 weeks
Reported as:
Least squares mean · scores on a scale
Change in Total PANSS Score From Baseline to the End of the Double Blind Phase
scores on a scaleLurasidone 40mgLurasidone 80mgLurasidone 120mgPlacebo
Change in Total PANSS Score From Baseline to the End of the Double Blind Phase-19.2 (-22.6 to -15.7)-23.4 (-26.9 to -19.9)-20.5 (-24.0 to -17.1)-17.0 (-20.5 to -13.6)
Statistical analysis
  • Lurasidone 40mg vs Lurasidone 80mg vs Lurasidone 120mg vs Placebo · Mixed Models Analysis · p = <0.05

Adverse events

Collected over 14 days post study therapy. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone 40mg—2/124 (1.6%)96/124 (77.4%)
Lurasidone 80mg—3/121 (2.5%)90/121 (74.4%)
Lurasidone 120mg—6/124 (4.8%)106/124 (85.5%)
Placebo—5/127 (3.9%)85/127 (66.9%)
Most frequent serious events
Most frequent serious events
EventLurasidone 40mgLurasidone 80mgLurasidone 120mgPlacebo
SchizophreniaPsychiatric disorders1/1241/1215/1241/127
Psychotic DisordersPsychiatric disorders0/1241/1211/1243/127
Staphylococcal InfectionInfections and infestations0/1241/1210/1240/127
Complex Partial SeizuresNervous system disorders1/1240/1210/1240/127
CholecystitisHepatobiliary disorders0/1240/1210/1241/127
Blood Lactate Dehydrogenase IncreasedInvestigations0/1240/1210/1241/127
Most frequent other events
Showing 10 of 13
Most frequent other events
EventLurasidone 40mgLurasidone 80mgLurasidone 120mgPlacebo
AkathisiaNervous system disorders14/12421/12130/12465/127
HeadacheNervous system disorders23/12416/12121/12420/127
SomnolenceNervous system disorders13/12412/12118/1247/127
NauseaGastrointestinal disorders14/1248/12115/1249/127
SedationNervous system disorders7/12413/12113/1246/127
DyspepsiaGastrointestinal disorders6/1247/12112/1246/127
VomitingGastrointestinal disorders5/1247/12112/1245/127
ParkinsonismNervous system disorders8/1245/12112/1240/127
InsomniaPsychiatric disorders8/1249/1216/12410/127
DystoniaNervous system disorders6/1249/1213/1241/127

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lurasidone 40mgLurasidone 80mgLurasidone 120mgPlaceboTotal
Mean40.7 ± 11.138.6 ± 9.537.7 ± 11.238.2 ± 9.938.8 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone 40mgLurasidone 80mgLurasidone 120mgPlaceboTotal
Female40433234149
Male82769290340
Region of Enrollment
Region of Enrollment(participants)Lurasidone 40mgLurasidone 80mgLurasidone 120mgPlaceboTotal
France01113
United States70647067271
Malaysia22228
Ukraine1312121451
Romania999936
Russian Federation1415131557
India1416171663
08

Study locations

48 sites
  • K&S Professional Research Services, LLC.
    Little Rock, Arkansas 72201, United States
  • Comprehensive Neuroscience, Inc
    Cerritos, California 90703, United States
  • Clinical Innovations, Inc.
    Costa Mesa, California 92647, United States
  • Collaborative Neuroscience Network Inc.,12772 Valley View Street,Suite 3
    Garden Grove, California 92645, United States
  • California Clinical Trials
    Paramount, California 90723, United States
  • Pasadena Research Institute
    Pasadena, California 91107, United States
  • California Neuropsychopharmacology,CNRI - Los Angeles LLC,8309 Telegraph Road
    Pico Rivera, California 90660, United States
  • Sharp Mesa Vista Hospital
    San Diego, California 92123, United States
  • Comprehensive Neuroscience, Inc.
    Washington, District of Columbia 20016, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34208, United States
  • Segal Institute for Clinical Research, Fidelity Clinical Research, Inc.
    North Miami, Florida 33161, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Alexian Brothers Health System
    Hoffman Estates, Illinois 60169, United States
  • Lake Charles Clinical Trials LLC
    Lake Charles, Louisiana 70601, United States
  • Booker, J. Gary, MD. APMC
    Shreveport, Louisiana 71104, United States
  • Center for Behavioral Health, LLC
    Rockville, Maryland 20850, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Erie County Medical Center, Corp
    Buffalo, New York 14215, United States
  • CRI Worldwide LLC at Kirkbride
    Philadelphia, Pennsylvania 19139, United States
  • Research Strategies of Memphis, LLC.
    Memphis, Tennessee 38119, United States
  • Future Search Trials of Neurology
    Austin, Texas 78756, United States
  • Hospital Caremeau
    Nimes, 30000, France
  • S V Medical College
    Tirupati, Andh Prad 517507, India
  • Government Hospital for Mental Care
    Visakhapatnam, Andh Prad 530017, India
  • Sheth Vadilal Sarabhai General Hospital
    Ahmedabad, Gujarat 380006, India
  • Shanti Nursing Home
    Aurangabad, Mahara 431005, India
  • Madras Medical College & Government General Hospital
    Chennai, Tamilnadu 600003, India
  • Deva Mental Health Care
    Varanasi, Uttar Prad 221005, India
  • Hospital Permai
    Johor Bahru, Johor 81200, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Spitalul Clinic Judetean de Urgenta Arad
    Arad, 310022, Romania
  • Spitalul de Psihiatrie Titan "Dr. Constantin Gorgos"
    Bucuresti, 030442, Romania
  • Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia
    Bucuresti, 041914, Romania
  • Centrul de Recuperare si Reabilitare Gura Ocnitei
    Gura Ocnitei, 130083, Romania
  • Spitalul Judetean Arges
    Pitesti, 110069, Romania
  • North State Medical University
    Arkhangelsk, 163060, Russian Federation
  • Republic Psychiatric Hospital
    Karelia, 111111, Russian Federation
  • City Psychoneurological Dispensary #7 (with Hospital)
    St. Petersburg, 190005, Russian Federation
  • City Psyhiatric Hospital #2 of St. Nikolay Chudotvorets
    St. Petersburg, 190121, Russian Federation
  • City Psychiatric Hospital #4
    St. Petersburg, 191119, Russian Federation
  • Bekhterev Psychoneurological Research Institute
    St. Petersburg, 193019, Russian Federation
  • City Psychiatric Hospital #3 of Skvortsov-Stepanov
    St. Petersburg, 197341, Russian Federation
  • Dnipropetrovsk Regional Clinical Hospital named Mechnikov
    Dnipropetrovsk, 49005, Ukraine
  • Reg. Clin. Psychiatric Hosp. DSMU n.af.M.Gorkiy
    Donetsk, 83037, Ukraine
  • Kyiv City Clin. Psychoneurolog. Hosp.#1
    Kyiv, 04080, Ukraine
  • Lv. St. Med. Univ. n. af. D. Halytskiy Oblast Clin. Psychon. Hosp
    Lviv, 79021, Ukraine
  • Odesa SMU, based on Odessa Reg. Psychiatric Hosp.#1
    Odessa, 65006, Ukraine
  • Kherson Regional Psychiatric Hospital
    vil. Stepanovka, Kherson, 73488, Ukraine
09

References and documents

Publications

  • Nasrallah HA, Silva R, Phillips D, Cucchiaro J, Hsu J, Xu J, Loebel A. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013 May;47(5):670-7. doi: 10.1016/j.jpsychires.2013.01.020. Epub 2013 Feb 17. PubMed 23421963 ↗
  • Hopkins SC, Ogirala A, Worden M, Koblan KS. Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS. Clin Drug Investig. 2021 Dec;41(12):1067-1073. doi: 10.1007/s40261-021-01094-7. Epub 2021 Nov 9. PubMed 34751928 ↗
  • Correll CU, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A. Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS Spectr. 2016 Oct;21(5):393-402. doi: 10.1017/S1092852915000917. Epub 2016 Apr 6. PubMed 27048911 ↗
  • Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 2015 Apr;20(2):140-7. doi: 10.1017/S1092852914000285. Epub 2014 Jun 23. PubMed 24955752 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2007
First posted
Oct 26, 2007
Start
Oct 2007
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Dec 14, 2010
Last update
Jun 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00549718
Responsible party
Sponsor
First posted
Oct 26, 2007
Start date
Oct 2007
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Dec 14, 2010
Last update
Jun 11, 2014

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion